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Abstract
Background: P-TEFb, a general RNA polymerase II elongation factor, is composed of CDK9
(cyclin-dependent kinase 9) as a catalytic unit and either cyclin T1, T2 or K as a regulatory subunit.
The cyclin T1/P-TEFb complex is targeted by HIV to mediate Tat transactivation. Cyclin T1 protein
expression is induced during early macrophage differentiation, suggesting a role in regulation of
mRNA expression during the differentiation process. To study the functional significance of cyclin
T1 induction during differentiation, we utilized the human Mono Mac 6 (MM6) monocytic cell line.
Results:  We found that cyclin T1 protein expression is induced by a post-transcriptional
mechanism following PMA treatment of MM6 cells, similar to its induction in primary monocytes
and macrophages. Also in agreement with findings in primary cells, cyclin T2a is present at relatively
high levels in MM6 cells and is not induced by PMA. Although the knock-down of cyclin T1 in MM6
cells by shRNA inhibited HIV-1 Tat transactivation, MM6 cell growth was not affected by the
depletion of cyclin T1. Using DNA microarray technology, we found that more than 20% of genes
induced by PMA require cyclin T1 for their normal level of induction, and approximately 15% of
genes repressed by PMA require cyclin T1 for their normal level of repression. Gene ontology
analysis indicates that many of these cyclin T1-dependent genes are related to immune response
and signal transduction.
Conclusion:  These results suggest that cyclin T1 serves a critical role in the program of
macrophage differentiation, and this raises questions about the feasibility of cyclin T1 serving as an
antiviral therapeutic target.
Background
Mammalian RNA polymerase II transcription (RNAP II) is
a complex and coordinated process and its regulation is
involved in many important cellular events such as differ-
entiation, activation, and stress response. While the regu-
lation of transcription initiation has been an actively
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studied area for decades, the regulation of transcription
elongation has not been as actively investigated until
recent years when a number of transcription elongation
factors have been identified [1]. One factor of particular
interest to transcriptional elongation is P-TEFb, a protein
kinase that appears to regulate expression of a large por-
tion of mammalian genes [2,3]. P-TEFb is believed to acti-
vate transcriptional elongation through phosphorylation
of the carboxyl-terminal domain of RNAP II, the Spt5 sub-
unit of the DSIF complex, and the RD subunit of the NELF
complex, therefore overcoming blocks to RNAP II proces-
sivity [4-6].
A number of distinct P-TEFb complexes exist in human
cells. All P-TEFb complexes contain CDK9 as the catalytic
subunit, either the major 42 kDa CDK9 protein or the 55
kDa CDK9 protein, a minor isoform containing an amino
terminal extension that arises from an upstream transcrip-
tional start site [7]. These CDK9 proteins are associated
with a regulatory cyclin subunit, which can be either cyc-
lin T1, T2a, T2b, or cyclin K [8]. The existence of different
P-TEFb complexes raises the possibility that distinct sets of
genes may be regulated by different P-TEFb complexes.
Consistent with this idea, the CDK9 42 kDa protein is
localized throughout the nucleoplasm, while the CDK9
55 kDa protein is concentrated in the nucleolus [9]. Addi-
tionally, the 55 kDa protein is expressed at relatively high
levels in resting lymphocytes and is not regulated by acti-
vation, while the 42 kDa protein is expressed at low levels
in resting lymphocytes and is upregulated by activation
[9]. Additionally, a large portion of P-TEFb is associated in
a large complex containing 7SK snRNA and HEXIM pro-
teins, either HEXIM I or HEXIM II [10-15]. This large P-
TEFb is catalytically inactive in vitro and it has been pro-
posed that 7SK snRNA and HEXIM proteins are negative
regulators of transcription elongation.
The best-characterized P-TEFb complex is cyclin T1/
CDK9, which is targeted by the human immunodeficiency
virus-1 (HIV-1) Tat protein to stimulate the transcription
elongation and therefore the replication of the integrated
HIV-1 genome [16,17]. Because of its important role in
HIV-1 replication, the inhibition of P-TEFb function has
been proposed as a potential therapeutic approach for
AIDS. Thus far, proposed methods of inhibiting P-TEFb
function include: small molecule inhibitors, anti-hCycT1
intrabodies, a dominant-negative CDK9 protein, and siR-
NAs against P-TEFb [18-23].
In human monocytes and macrophages, primary targets
of HIV-1 infection, we have previously observed complex
patterns of P-TEFb regulation. Cyclin T1 mRNA levels are
high but little protein expression can be observed in
monocytes freshly isolated from health blood donors
[24]. When monocytes are cultured under conditions that
induce macrophage differentiation, cyclin T1 protein
expression is induced to high levels within one to two
days. In contrast, CDK9 protein levels are generally high
in freshly isolated monocytes and are not strongly upreg-
ulated during differentiation. However, after approxi-
mately seven to ten days of macrophage differentiation in
culture, cyclin T1 protein expression is shut-off by protea-
some-mediated proteolysis that may target the PEST
sequence at the carboxyl terminus of cyclin T1 [25]. Mac-
rophage activators such as lipopolysacchride or other
pathogen-associated molecular patterns (PAMPs) can
reinduce expression of cyclin T1 after the shut-off, suggest-
ing that induction of cyclin T1 is a component of an
innate immune response [25]. Interestingly, HIV infection
can also induce cyclin T1 expression in the late-differenti-
ated macrophages [25]. In contrast to the regulated
expression of cyclin T1, the cyclin T2a subunit of P-TEFb
is present at relatively high levels in monocytes, it is not
shut off during differentiation, and it is not induced by
activation [26]. These data suggest that cyclin T2a and T1
might regulate the expression of different genes in mono-
cytes and macrophages. Moreover, the expression pattern
of cyclin T1 suggests that it may specifically regulate genes
important for macrophage early differentiation and the
innate immune response.
In this study, we report that in a monocytic cell line, Mono
Mac 6 (MM6), cyclin T1 protein expression is induced by
a post-transcriptional mechanism following PMA treat-
ment to induce macrophage differentiation, similar to the
induction of cyclin T1 in primary monocytes and macro-
phages. Also similar to primary cells, cyclin T2a is present
at relative high levels in MM6 cells and is not responsive
to differentiation signals. We found that although knock-
down of cyclin T1 in MM6 cells by shRNA inhibits HIV-1
Tat transactivation, it did not affect cell growth. Using
DNA microarray technology, we found that the knock-
down of cyclin T1 had a relatively small effect on mRNA
levels in MM6 cells prior to PMA treatment, consistent
with no obvious effect of the knock-down on cell growth.
However, more than 20% of genes induced by PMA
require cyclin T1 for their normal level of induction, and
approximately 15% of genes repressed by PMA require
cyclin T1 for their normal level of repression. These results
suggest that cyclin T1 serves a critical role in the PMA-
induced program of macrophage differentiation of MM6
cells. Therefore, the use of cyclin T1 as an antiviral thera-
peutic target may not be feasible.
Results
Establishment of a model system for investigation of cyclin 
T1 function in macrophage differentiation
The functional significance of the induction of cyclin T1
expression upon differentiation of primary monocytes is
unknown, in part due to the difficulty in biochemical andRetrovirology 2006, 3:32 http://www.retrovirology.com/content/3/1/32
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genetic manipulation of primary monocytes. To deter-
mine whether the induction of cyclin T1 protein can be
recapitulated in a transformed cell line that is more ame-
nable to functional studies, we examined the Mono-Mac-
6 (MM6) cell line that was derived from a human leuke-
mia patient [27]. MM6 cells exhibits characteristics of
mature monocytes, such as the expression of markers spe-
cific for mature monocytes which are absent in the less
mature and more commonly used U937 and THP1
human promonocytic cell lines [27]. To examine cyclin T1
expression in MM6 cells, a time-course experiment was
performed in MM6 cells using PMA treatment as the dif-
ferentiation agent (Fig. 1A). Following 24 hours of PMA
treatment, MM6 cells aggregated and became loosely
attached to the bottom of the culture dishes (data not
shown), mimicking the differentiation of monocytes into
macrophages. Cyclin T1 expression was low prior to the
treatment and an induction of its expression was observed
as early as six hours after PMA treatment and continued to
increase at 24 and 48 hours. In contrast, CDK9 and β-actin
were expressed at relatively constant high levels before
and after PMA treatment (Fig. 1A).
To determine whether the cyclin T1 induction in MM6
cells is specific to PMA, other differentiation inducers or
macrophage activators were tested for their effect on cyc-
lin T1 expression (Fig. 1B). Treatment of MM6 cells with
the differentiation inducers vitamin D3 or retinoic acid
showed strong induction of cyclin T1 at 24 and 48 hours
post-treatment, similar to that of PMA. Treatment of MM6
cells with the activators LPS or interferon-γ also showed a
strong induction of cyclin T1 at 24 and 48 hours post-
treatment (Fig. 1B).
The expression of cyclin T1 in primary macrophages is
known to be regulated post-transcriptionally, as the
mRNA for cyclin T1 is high in primary monocytes when
cyclin T1 protein expression is low and it does not
increase with the induction of cyclin T1 protein expres-
sion [24]. To examine whether the induction of cyclin T1
in MM6 cells is also regulated by a post-transcriptional
mechanism, the mRNA expression levels of cyclin T1 were
examined by quantitative RT-PCR analysis (Fig. 1C).
Although cyclin T1 protein expression was induced by
PMA (data not shown), the mRNA level of cyclin T1 did
not increase after the treatment of PMA and actually
decreased about 40%. This reduction in cyclin T1 mRNA
levels when cyclin T1 protein expression is up-regulated
has also been observed in primary monocytes [24]. The
mRNA level of CD11c, a marker for macrophage differen-
tiation that has previously been shown to be induced at
the mRNA level[28], increased over 30-fold following the
PMA treatment, whereas the mRNA level of CDK9
remained constant (Fig. 1C). Data shown in Figure 1 indi-
cate that the up-regulation of cyclin T1 expression in MM6
cells involves a post-transcriptional mechanism, similar
to that observed in primary monocytes. Therefore, MM6
cells appear to be a valid model system with which to
investigate the functional significance of cyclin T1 induc-
tion during the differentiation of primary monocytes to
macrophages.
Knock-down of cyclin T1 in MM6 cells by a lentiviral 
shRNA expression vector
To study the functional significance of the induction of
cyclin T1 during MM6 differentiation, a siRNA-based
strategy was used to knock down cyclin T1 expression.
MM6 cells, like many promonocytic cell lines, are refrac-
tory to transfection procedures [29] and we therefore used
a lentiviral shRNA expression vector. Additionally, the
continuous expression of the shRNA from the lentiviral
vector in the transduced cells has the advantage of a stable
knock-down of cyclin T1 mRNA, while transfected siRNAs
typically induce only a transient knock-down [18]. The
shRNA expression is driven by the human U6 promoter, a
promoter recognized by the RNA polymerase III enzyme
[30]. The vector also contains an eGFP expression cassette
driven by the human ubiquitin-C promoter. Importantly,
the lentiviral vector does not encode any lentiviral gene
products. The target sequence for cyclin T1 was selected by
a rational design strategy [31]. A control lentiviral vector
was constructed in which the shRNA contained a four-
nucleotide mismatch against the cyclin T1 mRNA.
Using a multiplicity of infection of five, >98% of MM6
cells were transduced five days post-infection with the len-
tiviral vectors (Fig. 2A). To examine the efficiency of the
knock-down, the mRNA and protein levels of cyclin T1
were measured by quantitative RT-PCR and immunoblot-
ting, respectively. The shRNA vector against cyclin T1
reduced cyclin T1 mRNA levels 4-fold relative to parental
cells treated with PMA (data not shown). The protein level
of cyclin T1 was also significantly knocked down by the
cyclin T1 shRNA vector before and after PMA treatment
(Fig. 2B). During the course of this study, we observed
that CDK9 protein levels were usually reduced when cyc-
lin T1 expression was knocked down by the shRNA vector.
For example, the level of CDK9 in the cells infected with
shRNA-CycT1 lentivirus was below that of the control
cells, both before and after PMA treatment (Fig. 2B). This
observation is consistent with previous findings which
have indicated that CDK9 protein stability appears to be
affected by the expression of cyclin T1 [18].
Knock-down of cyclin T1 inhibits HIV-1 transactivation by 
Tat
It is well established that cyclin T1 in the P-TEFb complex
is required for Tat-mediated transactivation of HIV-1 LTR-
directed gene expression [17]. To test whether the knock-
down of cyclin T1 in MM6 cells inhibits the cyclin T1/P-Retrovirology 2006, 3:32 http://www.retrovirology.com/content/3/1/32
Page 4 of 16
(page number not for citation purposes)
Cyclin T1 expression is induced in MM6 cells through a post-transcriptional mechanism Figure 1
Cyclin T1 expression is induced in MM6 cells through a post-transcriptional mechanism. (A) Cell extracts were 
prepared from untreated MM6 cells or MM6 cells treated with PMA from 1 to 48 hours as indicated. Immunoblots were per-
formed to measure levels of Cyclin T1 (CycT1), CDK9 and β-actin proteins. (B) Cell extracts were prepared from untreated 
MM6 cells (Con) or MM6 cells treated with PMA, vitamin D3 (VitD), retinoic acid (RA), LPS, or interferon gamma (IFNγ) for 24 
or 48 hours. Immunoblots were performed to measure levels of Cyclin T1, CDK9 and β-actin proteins. (C) Total RNA was 
isolated from untreated MM6 cells or cells treated with PMA for 24 hours. Quantitative real-time RT-PCR was used to meas-
ure the expression level of Cyclin T1, CDK9, and CD11c mRNA. The fold-change represents the change of transcript levels in 
PMA-treated MM6 cells relative to untreated cells after normalization to β-actin mRNA levels which are insensitive to PMA.Retrovirology 2006, 3:32 http://www.retrovirology.com/content/3/1/32
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TEFb complex and therefore Tat function in vivo, infec-
tions were carried out with two HIV-1 luciferase reporter
viruses: a virus expressing a wild-type Tat protein and a
mutant virus that expresses a non-functional Tat protein.
The Tat mutant, Tat-pro18IS has been shown previously
to abolish Tat trans-activation [32].
Non-transduced MM6 cells or cultures of MM6 cells trans-
duced with shRNA-CycT1 or shRNA-control lentiviruses
(five days post-transduction) were infected with either the
Tat+ or Tat- reporter virus. For the Tat- virus, luciferase
expression was at similar levels in all three infected cul-
tures. However, for the Tat+ virus, luciferase expression
shRNA against cyclin T1 expressed from a lentiviral vector can efficiently knock down cyclin T1 protein expression Figure 2
shRNA against cyclin T1 expressed from a lentiviral vector can efficiently knock down cyclin T1 protein 
expression. (A) Untransduced cells (Parental MM6 cells) or MM6 cells infected at a m.o.i. of five with lentiviral vectors 
expressing a shRNA against cyclin T1(shRNA-T1) or a control shRNA against a mismatch sequence in cyclin T1 (shRNA-Con) 
were analyzed by flow cytometry at day five post-infection. The lentiviral vectors express an eGFP marker protein. The per-
centages of the GFP positive cells are indicated. (B) Cell extracts were prepared at day five post-infection from the cultures 
described in A which were either untreated or treated with PMA for 24 hours. Immunoblots were performed to measure lev-
els of cyclin T1, CDK9 and β-actin proteins.Retrovirology 2006, 3:32 http://www.retrovirology.com/content/3/1/32
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was 6-fold lower in cells transduced with shRNA-CycT1
than in non-transduced cells or cells expressing the con-
trol shRNA (Fig. 3A). In general, Tat transactivation of the
HIV-1 LTR is low in monocytic cell lines relative to Tat
transactivations in many other cell lines [24,33].
To exclude the possibility that shRNA against cyclin T1
might affect steps in the virus life cycle prior to transcrip-
tion of the integrated provirus, MM6 cells were first
infected with either the Tat+ or Tat-reporter virus. Three
days later, the cultures were infected with the lentiviral
shRNA vectors. Cell extracts were prepared five days after
infection with shRNA vectors and luciferase expression
was assayed (Fig. 3B). Again, luciferase expression for the
Tat- virus was at similar levels in all three infected cultures.
However, for the Tat+ virus, luciferase expression was 5-
fold lower in cells infected with shRNA-CycT1 lentiviruses
than in non-transduced cells or cells infected with shRNA-
control (Fig. 3B). We conclude from these experiments
that the shRNA against cyclin T1 is effective in inhibiting
cyclin T1 function in vivo.
The knock-down of cyclin T1 in MM6 cells does not affect 
cell growth
We carried out a growth curve with MM6 cultures two
days after infection with the shRNA-CycT1 and shRNA-
control lentiviruses. Interestingly, cells expressing the
siRNA against cyclin T1 did not exhibit reduced growth, as
the culture infected with the shRNA-CycT1 lentivirus grew
at a rate equivalent to the culture infected with the shRNA-
control virus (Fig. 4A). We observed no increase in spon-
taneous apoptosis in cells infected with either lentiviral
vectors as determined by caspase-3 assays (data not
shown). Additionally, no significant difference in the cas-
pase-3 activity was observed in cell extracts prepared from
cultures shown in Fig. 4A that were PMA treated (data not
shown). The cultures infected with both shRNA-CycT1
and shRNA-control lentiviruses appeared to grow at a
slightly reduced rate relative to the parental MM6 cells
(Fig. 4A). However, the significance of this small differ-
ence is unclear. Additionally, we observed that cells
infected with either the shRNA-control or shRNA-CycT1
vector aggregated more than uninfected MM6 cultures
prior to PMA treatment, with the shRNA-control vector
displaying slightly greater aggregation than the shRNA-
CycT1 vector. We did not quantify this phenomenon and
its significance remains to be established.
Because the P-TEFb complex includes CDK9 and either
cyclin T1, T2a, T2b, or K, it is conceivable that cyclin part-
ners of CDK9 other than cyclin T1 might be sufficient for
P-TEFb function in MM6 cells depleted for cyclin T1
expression. We therefore examined cyclin T2a expression
in an immunoblot, and a relatively high level of cyclin T2a
expression was observed with or without the cyclin T1
knock-down (Fig. 4B). We also observed in immunoblots
that cyclin T2b was expressed at low levels in MM6 cells
containing the cyclin T1 knock-down (data not shown).
Additionally, the expression of cyclin T2a did not change
before or after PMA treatment (Fig. 4B). These observa-
tions suggest that cyclin T2a and T2b might be responsible
for constitutive gene expression in MM6 cells, whereas
cyclin T1 might play a more regulatory role in MM6 cells.
Knockdown of cyclin T1 inhibits Tat transactivation of HIV-1  proviral expression Figure 3
Knockdown of cyclin T1 inhibits Tat transactivation 
of HIV-1 proviral expression. (A) Non-transduced paren-
tal MM6 cells (MM6) or pool of MM6 cells expressing a 
shRNA against cyclin T1 (shRNA-T1) or a control shRNA 
(shRNA-Con) were infected with either a NL4-3-Luc (Tat+) 
HIV-1 luciferase reporter virus or a NL4-3-Luc-Tat- (Tat-) 
virus encoding a mutated Tat protein. Cell lysates were pre-
pared 48 hours post-infection and analyzed for luciferase 
activity using equal amounts of protein. Luciferase expres-
sions in extracts infected with the shRNA-Cyc T1 lentiviral 
vector were assigned an arbitrary value of 1.0 unit and other 
values are shown relative to this. A representative experi-
ment of this experimental design is shown. (B) MM6 cells 
were infected with either a Tat+ virus or a Tat- virus. After 
three days, they were either left uninfected or infected with 
lentivial vectors expressing a shRNA against Cyclin T1 or a 
control shRNA. Cell extracts were prepared five days post-
infection and assayed for luciferase expression. A representa-
tive experiment of this experimental design is shown.Retrovirology 2006, 3:32 http://www.retrovirology.com/content/3/1/32
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Cyclin T1 knockdown does not affect cell growth Figure 4
Cyclin T1 knockdown does not affect cell growth. (A) Two days after infection with either the shRNA-CycT1 or 
shRNA-control viruses (T1 and Con), 2 × 105 cells/ml of the infected or uninfected parental MM6 cell cultures (MM6) were 
seeded and counted at 24, 48, and 72 hours. (B) Cell lysates were prepared from cells with different treatments (as indicated), 
five days post-infection. Immunoblots were performed to determine the expression of cyclin T2a and β-actin.Retrovirology 2006, 3:32 http://www.retrovirology.com/content/3/1/32
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Transcriptional profiling: validation and analysis of 
microarray data
To identify genes regulated directly or indirectly by cyclin
T1 in both PMA-treated and Non-PMA-treated MM6 cells,
we performed a transcriptional profile analysis of cultures
of MM6 cells infected with the shRNA-CycT1 or shRNA-
control lentiviruses, as well as uninfected parental MM6
cells. Cultures were treated with or without PMA and the
RNA isolated from these cells were analyzed using
Affymetrix human genome U133 Plus 2.0 DNA arrays rep-
resenting about 18,953 unique (non-redundant) tran-
scripts. Three independent biological replicate
experiments were carried out in this analysis. In the first
two replicates, all three cultures of cells (parental MM6,
shRNA-CycT1, shRNA-control) were treated with or with-
out PMA. In the additional replicate, only cells treated
with PMA were analyzed.
To verify that the microarray data are reliable, several
mRNAs whose levels were up-regulated >2-fold by PMA
treatment and were also repressed >2-fold by shRNA-
CycT1 were selected for further analysis by real-time RT-
PCR assays: colony stimulating factor 1 receptor (CSF1-R),
oxidised low density lipoprotein (lectin-like) receptor 1
(OLR1), cyclin-dependent kinase inhibitor 1A (p21) and
complement component 5 receptor 1 (CD88). Chemok-
ine (C-X3-C motif) receptor 1 (CX3CR1) was selected as a
negative control, as its RNA levels was unaffected by the
cyclin T1 knock-down in the microarray data. Addition-
ally, RNA levels were normalized to β-actin whose level
was unaffected by PMA or knock-down of cyclin T1. The
fold-change of transcripts in shRNA-CycT1 cells were
compared with the parental MM6 cells (Fig. 5). In excel-
lent agreement with the microarray data, transcripts
encoding these genes were also repressed in cells express-
ing shRNA-CycT1. These data suggest that the microarray
data are in general reliable.
Affymetrix microarray data were processed in three steps:
1) normalization and derivation of expression measures;
2) analysis of expression measures with a linear model to
identify lists of differentially expressed genes; and 3) con-
tent analysis of the gene lists to distill biologically inter-
pretable content. All analyses were conducted in the R
open source language for statistical computing using both
the Bioconductor suite of R packages and locally devel-
oped R code[34].
Raw probe level intensity data were reduced to expression
measures using the gcrma method [35]. To examine the
pattern of differences in RNA populations from cultures
subjected to different treatments, a dendrogram was gen-
erated based on expression measures from all probe sets
on the array (Fig. 6). The 15 RNA samples were clearly par-
titioned into four groups: 1) shRNA-CycT1 cells without
PMA treatment; 2) shRNA-control and parental cells with-
out PMA treatment; 3) shRNA-CycT1 cells with PMA treat-
ment; 4) shRNA-control and parental cells with PMA
treatment. This grouping suggests that the knock-down of
cyclin T1 has a distinct gene expression profile from that
of shRNA-control or parental cells. Additionally, this
grouping suggests that the gene expression profiles from
the shRNA-control and parental cells are very similar to
each other and can be treated as a single control group.
To better understand the genes responsible for the pattern
observed in the dendrogram, a two-way ANOVA was fit to
each probeset using activation and knockdown state as
explanatory variables. A linear contrast analysis was then
performed to identify differentially expressed genes (see
below). The contrast analysis identified four distinct sets
of genes: PMA-induced, PMA-repressed, T1 knock-down-
induced-in-PMA-treated-cells, and T1 knock-down-
repressed-in-PMA-treated-cells. An empirical Bayes
method[36] was used to enhance variance estimation and
to improve the T-statistics for individual probe sets. Mul-
tiple testing corrections were made using the Linear Step
Down method[37]. Lists were formed using the rule that
a greater than 2-fold change in expression was estimated
between the treatments, and the adjusted false discovery
rate (FDR) value for the comparison was less than 0.05.
Finally, the genes identified in the various lists were sub-
jected to gene ontology (GO) content analysis[38]. GO
content analysis was performed by tabulating the list
against the GO structure. To perform the analysis, we cal-
culated the number of genes in the list annotated at or
Validation of the microarray data Figure 5
Validation of the microarray data. Cell cultures were 
infected with indicated shRNA lentiviral vectors for five days, 
treated with PMA for 24 hours, and total RNA was isolated. 
Quantitative real-time RT-PCR was used to measure the 
expression level of corresponding mRNA. The fold change 
represents the change of transcript levels in cells relative to 
parental MM6 cells after normalization with β-actin levels.Retrovirology 2006, 3:32 http://www.retrovirology.com/content/3/1/32
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below each GO node. This number is then compared
against the distribution of counts expected for a random
list of the same size. Statistical consideration of the counts
is based on a sampling without replacement model for
counts, treating the entire array as the universe of possible
genes from which a random list might be constructed. The
results indicated a large and distinctive family of differ-
ences between the content of the various lists. The ana-
lyzed microarray data can be downloaded from: http://
www.bcm.edu/molvir/labs/herrmann-rice-lab/
WY_MM6_T1-knockdown_PMA.zip.
Cyclin T1 is required for the appropriate expression of a 
sizable portion of mRNAs regulated by PMA
In our transcriptional profiling data, PMA treatment and
cyclin T1 knock-down are two major variables in the RNA
samples. The microarray data were therefore analyzed to
determine the effects of PMA treatment and knock-down
of cyclin T1 on RNA expression in MM6 cells.
We first examined the genes in control cells (no cyclin T1
knock-down) that were either induced or repressed by
PMA treatment. These 10 control samples (shRNA-control
and parental MM6 cells) were separated into two groups:
six PMA-treated samples and four untreated samples. A
statistical analysis of these control samples revealed that a
set of 1460 genes were upregulated >2-fold by PMA, and
1525 genes were downregulated >2-fold by PMA, with an
adjusted FDR value of P < 0.05. Thus, in control cells,
7.7% of genes assayed (1460 of 18,953) were induced >2-
fold by PMA, while 8.0% of genes (1525 of 18,953) were
repressed >2-fold by PMA (Table 1).
The number of genes that were affected by the depletion
of cyclin T1 in cells without PMA treatment was calcu-
lated. The two shRNA-CycT1 samples from non-PMA
treated cells were compared with two shRNA-control sam-
ples. A statistical analysis of these samples revealed that a
set of 131 genes were repressed >2-fold in the shRNA-
CycT1 samples, and 87 genes were induced >2-fold in the
shRNA-CycT1 samples, with an adjusted FDR value of P <
0.05. Thus, in non-PMA treated cells, 0.5% of genes
assayed (131 of 18,953) were repressed >2-fold by
shRNA-CycT1, while 0.7% of genes (87 of 18,953) were
induced >2-fold by shRNA-CycT1 (Table 1).
We next examined the number of genes that were affected
by cyclin T1 knock-down in cells treated with PMA. The
three PMA-treated shRNA-CycT1 samples were compared
with three PMA-treated shRNA-control samples. A statisti-
cal analysis revealed that following PMA treatment, a set
of 438 genes were repressed >2-fold by the cyclin T1
knock-down, while 399 genes were induced >2-fold by
the knock-down (P < 0.05). Thus, in these PMA-treated
cells, 2.3% of genes assayed (438 of 18,953) were
expressed at lower levels in cyclin T1 knock-down cells,
while 2.1% of genes (399 of 18,953) were expressed at
higher levels in cyclin T1 knock-down cells (Table 1).
To examine globally how the set of PMA-regulated genes
in MM6 cells are affected by the knock-down of cyclin T1,
we examined the effect of the knock-down on probe sets
that were either induced or repressed >2-fold by PMA
treatment in parental and shRNA-control cells. For every
probe set, its fold-change in shRNA-CycT1 versus shRNA-
control was calculated, with a negative score representing
downregulation by the knock-down and a positive score
Cyclin T1 knockdown cells have a distinct gene profile com- pared to control cells Figure 6
Cyclin T1 knockdown cells have a distinct gene pro-
file compared to control cells. A dendrogram was con-
structed based on the data from all probe sets for all 15 
arrays used in the study. The Pearson Correlation distance 
was calculated to represent the expression differences 
between the arrays. The leaves of the tree represent each of 
the 15 arrays used in this study. The branches denote the rel-
ative distances between the samples. Branch joins near the 
leaves of the tree represent high similarity, while deeper 
joins represent less similarity.Retrovirology 2006, 3:32 http://www.retrovirology.com/content/3/1/32
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representing upregulation by the knock-down, A histo-
gram was then generated based on the distribution of the
scores of all the probe sets that were either upregulated or
downregulated by PMA (Fig. 7). We examined the effect of
cyclin T1 on gene expression in untreated cell and PMA-
treated cells separately. In untreated cells, most probe sets
had scores between -2 and 2, suggesting that cyclin T1 has
little effect (<2-fold) on the set of PMA-regulatable genes
(Fig. 7). We do note, however, that in non-PMA-treated
cells the cyclin T1 knock-down induced a small number of
PMA-upregulated genes >2-fold, suggesting a very low
level of activation occurred following the shRNA-CycT1
lentivirus infection (Fig. 7A). In PMA-treated cells, an
obvious shift was observed in the distribution of the fold-
changes caused by the cyclin T1 knock-down in those
PMA-regulatable genes. For genes that are PMA-inducible,
a leftward shift was observed and a sizeable number of
genes were downregulated >2-fold by knock-down of cyc-
lin T1 (Fig 7A). For genes that are PMA-repressed, a right-
ward shift was observed and a sizeable number of genes
were upregulated more than >2-fold by knock-down of
cyclin T1 (Fig. 7B). Overall, these data indicate that the
level of induction of a significant fraction of PMA-induci-
ble genes is repressed by cyclin T1 depletion, and likewise,
the level of repression of a significant fraction of PMA-
repressed genes is induced by cyclin T1 depletion.
To quantify the minimum number of PMA-regulated
genes affected by the knock-down of cyclin T1, the list of
genes affected by cyclin T1 knock-down were compared to
the list of genes affected by PMA treatment in the control
group (Fig. 7C). We found that 303 of 1460 (20.8%)
PMA-inducible genes were repressed by cyclin T1 knock-
down. In contrast, <1% of the PMA-insensitive genes and
1.2% of the PMA-repressed genes were repressed by cyclin
T1 knock-down. Similarly, 238 of 1525 (15.6%) PMA-
repressed genes were expressed at higher levels in cyclin
T1 knock-down cells. In contrast, <1% of the PMA-insen-
sitive genes and 1.6% of PMA-inducible genes, were
induced by cyclin T1 knock-down. This observation
strongly suggests that cyclin T1 specifically modulates
expression of a substantial fraction of genes that are regu-
lated by PMA. Our data suggests that the induction of cyc-
lin T1 in PMA-treated cells contributes to the induction of
a minimum of 21% of PMA-inducible genes and a mini-
mum of 16% of PMA-repressed genes.
Genes involved in immune response are over-represented 
in the set of genes affected knock-down of cyclin T1
A Gene Ontology analysis was performed to identify the
biological processes mediated by genes induced in PMA-
treated MM6 cells. GO provides an organized vocabulary
of terms that can be used to describe a gene product's
attributes [39]. For the group of genes included in each
GO term, a significance value is computed from the
microarray data. This value (P value) is used to identify
biological processes that are either over-represented or
under-represented in those RNAs whose expression levels
are altered by different conditions.
For genes induced by PMA in control samples, the over-
represented biological processes were largely related to
immune responses, signal transduction, cell proliferation
and apoptosis (Fig. 8A). This pattern was expected, as
PMA induces a program of macrophage differentiation in
MM6 cells, and these biological processes are known to
affect macrophage function and the differentiation pro-
gram.
We next performed a GO analysis for the PMA-inducible
genes that were inhibited by the knock-down of cyclin T1
(Fig. 8B). A GO profile was obtained that was related but
nonetheless distinct from that seen in PMA-induced
genes. The GO terms that are related to cell proliferation,
cell cycle and apoptosis seen in the PMA-inducible genes
were not over-represented in the genes that were affected
by cyclin T1 knock-down. A comparison between those
two GO analyses (data not shown) revealed that the GO
terms related to immune response were more significantly
over-represented in the genes inhibited by knock-down of
cyclin T1 than in control PMA-treated cells. This suggests
that the knock-down of cyclin T1 may specifically affect
genes related to the immune response.
Discussion
Although the induction of cyclin T1 is observed during
early macrophage differentiation, its functional signifi-
cance was unknown prior to this study, due to the diffi-
culty in biochemical and genetic manipulation of primary
monocytes. In this study, we used MM6 cells as a model
system to study the regulation and function of cyclin T1
during the monocyte differentiation process. Cyclin T1
was induced in MM6 cells upon PMA treatment by a post-
Table 1: Number of genes induced or repressed >2-fold by different treatments
Induced Repressed
Non-PMA-treated vs PMA-treated (shRNA-con & parental cells) 1460 (7.7%) 1525 (8.0%)
shRNA-T1 vs shRNA con (non-PMA-treated cells) 87 (0.5%) 131 (0.7%)
shRNA-T1 vs shRNA con (PMA-treated cells) 399 (2.1%) 438 (2.3%)Retrovirology 2006, 3:32 http://www.retrovirology.com/content/3/1/32
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Cyclin T1 specifically affects genes regulated by PMA Figure 7
Cyclin T1 specifically affects genes regulated by PMA. (A) For probe sets that were induced >2-fold by PMA treatment, 
fold-change for shRNA-T1 versus shRNA-Con treatment was calculated. Based on magnitude of the fold-change, a total of 26 
categories (bins) were created. The first bin included all the probe sets with a fold-change < -8 and the last bin included all the 
probe sets with a fold-change >8. For bins between -8- and 8- fold (-3 to 3 after log2 transformation), the probe sets were 
divided into 24 bins with a log2 transformed value of 0.25 as the range for each bin (-3 to -2.75, -2.75 to -2.5, etc.). The number 
of probe sets in each bin (frequency) was tabulated and is shown on the Y axis. A histogram was generated based on the fre-
quencies in each corresponding bin, representing the distribution of the fold-changes for those probe sets. The black solid line 
represents the histogram generated from microarray data from non-PMA-treated cells, while the red broken line represents 
the histogram generated from the microarray data from PMA-treated cells. (B) For the probe sets that were repressed >2-fold 
by PMA treatment, fold-change for shRNA-T1 versus shRNA-Con treatment in non-PMA-treated or PMA-treated cells was 
calculated. A histogram was generated as described above based on the distribution of the fold-changes of those probe sets. 
(C) Genes that were either upregulated or downregulated by cyclin T1 knock-down were divided into three classes: PMA-
induced genes (PMA-Up), PMA-insensitive genes, and PMA-repressed genes (PMA-Down). Number of genes in each category 
was calculated from the microarray data. Those numbers were then divided by the total numbers for the PMA-induced genes, 
PMA-repressed genes, or PMA-insensitive genes to obtain the corresponding percentage.Retrovirology 2006, 3:32 http://www.retrovirology.com/content/3/1/32
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Gene Ontology analysis Figure 8
Gene Ontology analysis. GO content analysis was performed by tabulating the various gene lists against the GO structure. 
(A) Biological processes that were over-represented in the PMA-inducible genes compared to a random list of the same size. 
The color of each GO term was assigned corresponding to its adjusted P-value, while color intensity representing the adjusted 
P-value is indicated by color scaling. (B) Similar analysis was performed on genes induced by PMA and repressed by shRNA-T1. 
The color of each GO term was assigned corresponding to its adjusted P-value, while color intensity representing the adjusted 
P-value is indicated by color scaling.Retrovirology 2006, 3:32 http://www.retrovirology.com/content/3/1/32
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transcriptional mechanism, similar to its induction in pri-
mary monocytes and macrophages. Although the knock-
down of cyclin T1 in MM6 cells by shRNA inhibited HIV-
1 Tat transactivation, MM6 cell growth was not affected by
the depletion of cyclin T1. Using DNA microarray tech-
nology, we found that more than 20% of genes induced
by PMA require cyclin T1 for their normal level of induc-
tion, and more than 15% of genes repressed by PMA
require cyclin T1 for their normal level of repression. Gene
ontology analysis indicates that a high portion of these
cyclin T1-dependent genes are related to the immune
response and signal transduction. These results suggest
that cyclin T1 serves a critical role in the program of mac-
rophage differentiation.
We found that cyclin T1 protein expression is induced by
a post-transcriptional mechanism after the treatment of
MM6 cells by several different differentiation inducers
and activators (Fig. 1). These observations in MM6 cells
are similar to our previous findings in primary human
monocytes, where the induction of cyclin T1 early during
differentiation to macrophages also occurs by a post-tran-
scriptional mechanism. Furthermore, a gene ontology
analysis of mRNAs induced in MM6 cells by PMA demon-
strated an over-representation of genes that are related to
the immune response, signal transduction, cell growth
and apoptosis – biological processes known to be
involved in monocyte and macrophage differentiation or
function (Fig. 8). Our data indicate that MM6 cells are a
valid model system with which to study the functional
role of cyclin T1 during macrophage differentiation.
To our surprise, the stable knock-down of cyclin T1 in
MM6 cells did not measurably affect cell growth (Fig. 4),
although it did result in an inhibition of Tat-dependent
HIV-1 gene expression (Fig. 3), indicating that cyclin T1/
P-TEFb function was reduced. In non-PMA-treated MM6
cells, the great majority of cellular genes were not affected
by the depletion of cyclin T1, as only 131 genes (0.7% of
the genes analyzed) were repressed >2-fold and 87 genes
(0.5%) were induced >2-fold. The high level of cyclin T2a,
an alternative cyclin partner of CDK9 in MM6 cells, might
be sufficient to sustain adequate P-TEFb levels and there-
fore general gene transcription elongation following the
cyclin T1 knock-down. In MM6 cells, it is possible that
cyclin T1 and T2 have largely redundant functions and the
knock-down of cyclin T1 may be almost fully compen-
sated by cyclin T2a (or T2b). Alternatively, because cyclin
T1 is expressed at a low level in the non-activated MM6
cells, it may play a more regulatory role, while cyclin T2
may be responsible for expression of the set of constitu-
tively expressed genes in monocytic cells. In agreement
with this, we have recently observed that cyclin T2a is also
expressed constitutively in primary human monocytes
and is not induced by differentiation or macrophage acti-
vation [26].
Although non-PMA-treated MM6 cells with the knock-
down of cyclin T1 grow well, cyclinT1 expression appears
to be required for the regulated expression of a sizeable
portion of PMA-regulated genes, both those inducible and
repressed by PMA treatment (Fig. 7). Greater than 20% of
genes induced by PMA require cyclin T1 for their normal
level of induction, while greater than 15% of genes
repressed by PMA require cyclin T1 for their normal level
of repression. Therefore, cyclin T1 is likely to play an
important role in MM6 differentiation. It is important to
note that our data does not address whether the genes
affected by the depletion of cyclin T1 are direct targets of
cyclin T1/P-TEFb, rather than the results of indirect effects
that arise from a cascade of gene expression. Nonetheless,
it is clear that the knock-down of cyclin T1 preferentially
affects the expression of PMA-regulated genes rather than
a representative subset of all genes expressed in non-stim-
ulated MM6 cells.
The cyclin T1 knock-down specifically affects the mRNA
levels of many genes related to the immune response and
signal transduction in MM6 cells. In late-differentiated
primary macrophages, cyclin T1 expression is shut off by
proteasome-mediated proteolysis and can be reinduced
with activation by LPS or other PAMPs. The re-induction
of cyclin T1 in macrophage by PAMP activation suggests
that cyclin T1 may have an important role in the innate
immune response. It seems likely that there is considera-
ble overlap between genes in MM6 cells that are affected
by the knock-down of cyclin T1 and the genes affected by
the re-induction of cyclin T1 in late-differentiated macro-
phages. It is notable that HIV-1 can induce the expression
of cyclin T1 protein in primary macrophages, and there-
fore hijack this component of an innate immune response
to enhance viral replication [25].
Tat transactivation is highly dependent on cyclin T1/P-
TEFb function, and inhibitors of this cellular function,
such as small molecules, a dominant CDK9 protein, anti-
hCycT1 intrabodies, and siRNA against P-TEFb, are effec-
tive in reducing HIV-1 replication in vitro [18-23]. We
have shown that the knockdown of cyclin T1 in MM6 cells
has a pronounced effect on Tat transactivation during
HIV-1 infection. The cyclin T1 depletion described here,
similar to previous studies in HeLa or 293T cells, did not
measurably affect the growth of MM6 cells. However, the
cyclin T1 knockdown preferentially affected PMA-regu-
lated genes and therefore it is likely that the depletion of
cyclin T1 in primary macrophages will affect the innate
immunity and macrophage activation. Therefore, the use
of shRNA or siRNA to deplete cyclin T1 and reduce TatRetrovirology 2006, 3:32 http://www.retrovirology.com/content/3/1/32
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function may not be feasible as an antiviral therapeutic
strategy.
Finally, identification of genes regulated by cyclin T1 may
eventually help identify novel cellular factors important
for HIV-1 replication. Cyclin T1 in the P-TEFb complex is
required for Tat-mediated transactivation of HIV-1 LTR-
directed gene expression. It is possible that the induction
of cyclin T1 and the consequent upregulation of cyclin T1-
dependent genes may provide a permissive environment
of HIV-1 replication. Therefore, by using the cyclin T1/P-
TEFb complex as a cofactor, the virus may assure an opti-
mal cellular environment for maximal virus production.
Further analysis of the genes regulated by cyclin T1 may
lead to the identification of additional cellular factors
important for HIV-1 replication.
Conclusion
HIV targets the cyclin T1/P-TEFb complex to mediate Tat
transactivation. Cyclin T1 is also induced during mono-
cyte differentiation. The functional significance of cyclin
T1 was studied in MM6 cell as a model system for mono-
cyte differentiation. Although cell growth was not affected
by depletion of cyclin T1, cyclin T1 seems to play an
important role in regulating a large portion of mRNA
related to the differentiation program. This raises ques-
tions about using cyclin T1 as a therapeutic target for HIV-
1 infection.
Methods
Cell culture and reagents
Mono-Mac-6 cells were a gift from Dr. Jorge Benach (State
University of New York at Stony Brook). Cells were main-
tained in RPMI 1640 medium (Invitrogen) supplemented
with 10% heat-inactivated fetal bovine serum (FBS,
Hyclone), non-essential amino acids (Invitrogen), l-
glutamine (Invitrogen), and OPI media supplement
(Sigma) containing 0.15 mg of oxalacetate, 0.5 g of pyru-
vate and 8.2 mg of bovine insulin. For activation experi-
ments, MM6 cells were treated at a final concentration of
10 ng/ml phorbol 12-myristate 13-acetate (PMA, Sigma),
50 nM vitamin D3 (Sigma), 25 uM retinoic acid (Sigma),
1 ng/ml lipopolysacchride (LPS, Sigma) and 500 U/ml
interferon gamma (R&D systems).
Cell extracts and immunoblotting
Cell extracts were prepared by incubating cells in lysis
buffer (50 mM Tris, 120 mM NaCl, 0.5% NP-40) contain-
ing protease inhibitors (2 μg/ml aprotinin, 1 μg/ml leu-
peptin, 2.5 mM phenylmethylsulfonyl fluoride) as
described previously [33]. Protein concentrations were
determined by a Bio-Rad protein assay, and 20 μg of total
protein was loaded onto sodium dodecyl sulfate-9% poly-
acrylamide gels. The procedure for immunoblots using
enhanced chemiluminescence for detection has been
described previously[40]. Antibody to β-actin was pur-
chased from Sigma, and other antibodies were purchased
from Santa Cruz Biotechnology.
shRNA design, Lentivial production and flow cytometry
The target sequences used for this study were: shRNA-
CycT1: GCAGCGTCTTAACGTCTCA; shRNA-Control:
GCTATAGCTGTTCTAGTTC. Oligo-nucleotides contain-
ing the target sequences with overhangs compatible with
restriction enzyme sites were purchased from Invitrogen.
The annealed oligonucleotides were inserted into a hU6-
1 plasmid vector immediately after the human U6 pro-
moter. The U6 promoter driven-shRNA expressing cas-
settes were then subcloned into the FG12 lentiviral vector.
The FG12 vector is a self-inactivated lentiviral vector car-
rying an eGFP expression-cassette; the vector does not
encode any viral gene products [41].
Stocks of the FG12 lentiviral vectors pseudotyped with
vesicular stomatitis virus (VSV)-G were produced by cal-
cium phosphate-mediated transient transfection of HEK-
293T cells. Briefly, HEK-293T cells were cultured in
DMEM (GIBCO Invitrogen) containing 10% FBS
(HyClone), 100 units of penicillin, and 100 μg/ml strep-
tomycin. The cells were cotransfected with 5 ug of each
plasmid: vector plasmid, the HIV-1 lentiviral packaging
constructs pRSV/REV and pMDLg/pRRE, and the VSV-G
expression plasmid pHCMV-G. Virus stocks were col-
lected from the culture supernatants on days two post-
transfection and were titered on HEK-293T cells based on
GFP expression. MM6 cells (2 × 105/ml) were transduced
at a multiplicity of infection (m.o.i.) of five in the pres-
ence of 5 ng/ml polybrene (Sigma).
To determine transduction efficiencies, five days after len-
tiviral infection cells were suspended at 1 × 106 cells/ml in
phosphate-buffered saline (PBS) with 2% FBS and the
percentage of GFP positive cells were determined by flow
cytometry using a Beckman-Coulter XL-MCL cytometer.
HIV-1 luciferase virus production and luciferase assay
The HIV-1 reporter virus NL4-3-Luc (Tat+) was pseudo-
typed with VSV-G envelope protein and contains the fire-
fly luciferase gene in place of Nef. A Tat-  NL4-3-Luc
reporter virus (Tat-) was generated by introducing an EcoR
I restriction enzyme site after proline 18 in the Tat coding
sequence, which abolishes Tat transactivation func-
tion[32]. Stocks of Tat+ and Tat- NL4-3-Luc viruses were
produced by calcium phosphate-mediated transient trans-
fection of HEK-293 T cells, with cotransfection of the VSV-
G expression plasmid pHCMV-G and the Tat expression
plasmid pCMV-Tat. To assay for luciferase production,
cells lysates were prepared with Cell Culture Lysis Buffer
(Promega). The luciferase assay was performed accordingRetrovirology 2006, 3:32 http://www.retrovirology.com/content/3/1/32
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to the manufacturer's protocol (Promega), and the prod-
ucts were measured by a luminometer (Turner).
Microarray analysis
Microarray analysis was performed by the Baylor Microar-
ray Core Facility (Baylor College of Medicine, Houston,
TX 77030, USA). Detailed protocols can be found at the
website: http://www.bcm.edu/mcfweb/. Briefly, RNA was
isolated using the Qiagen RNeasy kit according to the
manufacturer's protocol and RNA quality was determined
using an Agilent 2100 Bioanalyzer. RNA was reverse tran-
scribed to generate cDNA and transcribed using T7 RNA
polymerase and biotinylated ribonucleotides to generate
labeled cRNA. Fragmented cRNA was hybridized to U133
plus 2.0 human gene chips (Affymetrix) containing nearly
55,000 probe sets representing over 18,953 transcripts.
Following washing and staining, the arrays were scanned
using an Affymetrix Gene Chip Scanner 3000. For all
experiments, the 5'/3' ratios of GAPDH ranged between
0.85 and 0.91. Comparisons of matched control and were
performed for each of three independent experiments.
Realtime PCR analysis
Quantitative real-time RT-PCR was performed using the
Bio-Rad MyIQ single color detection system. Cellular RNA
was used to perform cDNA synthesis using the iScript
cDNA synthesis kit (Bio-Rad). Briefly, 1 μg of RNA was
reverse transcribed in a 20-μl reaction volume using the
manufacturer's protocol. PCR reactions were performed
using 3 μl of cDNA in a 50 μl reaction containing 25 μl of
2X iQ SYBR Green Supermix (Bio-Rad) and 200 nM final
concentration of each primer. PCR reactions were carried
out in 96-well format using a Bio-Rad iCycler with a 3 min
hot start followed by 40 cycles of 15 s at 95°C, 1 min
annealing and amplification at 55°C. Analysis was per-
formed using the MyIQ software program (Bio-Rad). The
threshold crossing (Ct) value for each reaction was deter-
mined and the fold-change (ΔΔCt value) was calculated
with the following formulas using GAPDH as a reference
control:
Primers for quantitative PCR were designed using Beacon
Designer 2.0 (Premier Biosoft). All primer pairs produced
single amplification products as determined by gel elec-
trophoresis as well as melt-curve analysis using the MyIQ
system. Primers used were (5' to 3'): β-actin (forward):
AGCAAGCAGGAGTATGACGAGTC,  β-actin: AGAAAG-
GGTGTAACGCAACTAAGTC (reverse), CSF1R(forward):
TTCTGCTGCTCCTGCTGGTG, CSF1R(reverse): ACCGTT-
GCTCCTGGCTTCAC, LOX1(forward): ACTGTGAAG-
GACCAGCCTGATG, LOX1(reverse):
CCTAGAGTCGCAGCAGCCAG, CD88(forward): TCAAG-
GTGGTGGTGGCAGTG, CD88(reverse): GTGACGAT-
GGCTCCAGGAAGG, P21(forward):
AGCAGCGGAACAAGGAGTCAG, P21(reverse): GCCCT-
GTCCATAGCCTCTACTG, cyclin T1 (forward) AACCT-
TCGCCGCTGCCTTC, cyclin T1 (reverse)
ACCGTTTGTTGTTGTTCTTCCTCTC, Cdk9 (forward)
AGCACCAACTCGCCCTCATC, Cdk9 (reverse)
TTCAGCCTGTCCTTCACCTTCC.
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